Treatment of Alcohol Use Disorder in Patients with Liver Disease

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

DA

Divya Ayyala-somayajula, MD MAS

Assistant Professor of Medicine
Thomas Jefferson University
PHILADELPHIA, Pennsylvania
Thomas Bottyan, MD

Addiction Psychiatrist
VA Northern California
Mather, California
ST

Steven Tate, MD, MSc, FASAM, FACP

Clinical Assistant Professor
Stanford University School of Medicine
San Francisco, California
Deirdra Kelly, MD

Psychiatry Resident
University of California Davis
Sacramento, California

Slides Handouts

Non-presenting author(s)

Gargi Bhattacharya, MD

Fellow, Addiction Medicine
Stanford University School of Medicine
Stanford, California

This session provides practical, evidence-based guidance for treating Alcohol Use Disorder (AUD) in patients with liver disease across inpatient, outpatient, and transplant settings. Participants will gain tools to navigate treatment decisions, improve clinical outcomes, and support equitable care.

Learning Objectives:

Learners will be able to:

Evaluate the evidence and safety data for FDA-approved and off-label AUD pharmacotherapies in patients with liver disease, identifying indications and contraindications.
Develop safe and effective, evidence-based treatment plans for AUD in patients pre- and post-liver transplant.
Integrate psychosocial, mutual-support, and integrated care models into the management of AUD for patients with hepatic dysfunction.

Disclosure(s):

Divya Ayyala-somayajula, MD MAS: No financial relationships to disclose

Thomas Bottyan, MD: No financial relationships to disclose

Steven Tate, MD, MSc, FASAM, FACP: No financial relationships to disclose

Deirdra Kelly, MD: No financial relationships to disclose

Gargi Bhattacharya, MD: No financial relationships to disclose